| abstract |
A novel antibody therapy is provided. Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with a non-crosslinkable reactive cysteine amino acid. Methods for the design, preparation, screening and selection of the cysteine engineered anti-TENB2 antibody are provided. A cysteine engineered anti-TENB2 antibody (Ab) is conjugated via one or more drug moieties (D) via a linker (L) to have a formula I: Ab- (LD) p I An antibody-drug conjugate is formed, where p is 1-4. Diagnostic and therapeutic uses for the use of cysteine engineered antibody drug compounds and compositions are disclosed. [Selection figure] None |